Faris Halilovic
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Faris Halilovic has a total of 26 co-authors. Here are the top co-authors by number of shared publications:
- Hamideh Parhiz
Department of Systems Pharmacology and Translational Therapeutics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA
13 shared publications - Tyler Ellis Papp
Department of Systems Pharmacology and Translational Therapeutics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA
13 shared publications - Adrian Bot
Capstan Therapeutics, San Diego, California
11 shared publications - Carl H. June
University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania, United States
11 shared publications - Drew Weissman
University of Pennsylvania
11 shared publications - Ellen Puré
Department of Biomedical Sciences, University of Pennsylvania, Philadelphia, USA
11 shared publications
Latest Publications
- Open Access
- 27 May 2026
- Published by American Society of Hematology in Blood Advances
- Vol. 10 (11) , 3820-3831
Targeted LNP-mediated delivery of VE-cadherin mRNA reduces vascular hyperpermeability in vivo
Blood vessel hyperpermeability underlies a wide spectrum of potentially fatal diseases, ranging from acute pulmonary edema to brain injuries such as ischemic stroke. However, effective strategies for rapid rehabilitation of the vascular endothelium to restore vascular homeostasis remain lacking. Here, we developed a messenger RNA (mRNA) therapeutic encoding the vascular membrane structural protein vascular endothelial-cadherin (VEc), delivered via an anti-CD31 targeted lipid nanoparticle (aCD31/tLNP-VEc) directly to CD31+ vascular endothelial cells, for the rapid restoration of vascular integrity. We showed that administration of a single dose of aCD31/tLNP-VEc significantly ameliorates pathological onset in multiple mouse models of vascular hyperpermeability. In a bleomycin-induced lung edema model, we found aCD31/tLNP-VEc treatment significantly reduced fluid extravasation and decreased macrophage infiltration. In a transient middle cerebral artery occlusion-induced ischemic stroke model, aCD31/tLNP-VEc delivered postinjury diminished plasma protein leakage associated with brain edema by 50%. Targeted LNP-mediated delivery of VEc mRNA to the vascular network presents a promising platform for treating clinically relevant conditions involving vascular disruption.
- 27 May 2026
- Published by American Society of Hematology in Blood Advances
- Vol. 10 (11) , 3820-3831
Open AccessTargeted LNP-mediated delivery of VE-cadherin mRNA reduces vascular hyperpermeability in vivo
Blood vessel hyperpermeability underlies a wide spectrum of potentially fatal diseases, ranging from acute pulmonary edema to brain injuries such as ischemic stroke. However, effective strategies for rapid rehabilitation of the vascular endothelium to restore vascular homeostasis remain lacking. Here, we developed a messenger RNA (mRNA) therapeutic encoding the vascular membrane structural protein vascular endothelial-cadherin (VEc), delivered via an anti-CD31 targeted lipid nanoparticle (aCD31/tLNP-VEc) directly to CD31+ vascular endothelial cells, for the rapid restoration of vascular integrity. We showed that administration of a single dose of aCD31/tLNP-VEc significantly ameliorates pathological onset in multiple mouse models of vascular hyperpermeability. In a bleomycin-induced lung edema model, we found aCD31/tLNP-VEc treatment significantly reduced fluid extravasation and decreased macrophage infiltration. In a transient middle cerebral artery occlusion-induced ischemic stroke model, aCD31/tLNP-VEc delivered postinjury diminished plasma protein leakage associated with brain edema by 50%. Targeted LNP-mediated delivery of VEc mRNA to the vascular network presents a promising platform for treating clinically relevant conditions involving vascular disruption.
- Open Access
- 2 April 2026
- Published by American Association for Cancer Research (AACR)
Data from Targeted Lipid Nanoparticle Delivery of FAP-CAR mRNA Enables Potent In Vivo T-cell Engineering against Pancreatic Tumors
Fibroblast activation protein (FAP), which is highly expressed on cancer-associated fibroblasts (CAF), is a promising therapeutic target to achieve normalization of the tumor microenvironment. We previously established an ex vivo retroviral-transduced FAP-specific chimeric antigen receptor (FAP-CAR) T-cell approach to deplete FAP+ CAFs that resulted in delayed tumor growth associated with disruption of desmoplastic matrix and enhanced immune cell infiltration and reversed immune exclusion and immunosuppression. In this study, we describe an in vivo strategy for generating FAP-CAR T cells using anti-CD5–conjugated targeted lipid nanoparticles (tLNP) encapsulating FAP-CAR mRNA and assessed the efficacy of this approach compared with adoptive transfer of retrovirus-transduced CAR T cells in a preclinical model of pancreatic ductal adenocarcinoma. With transient CAR expression in >45% of splenic, >69% of circulating, and >35% of tumor-infiltrating T cells, the abundance of peripheral and intratumoral FAP-CAR+ T cells detected following a single intravenous dose of FAP-CAR mRNA tLNPs was greater than that detected following administration of 1 × 107ex vivo retrovirally transduced FAP-CAR T cells. Furthermore, in vivo mRNA CAR T-cell engineering resulted in as good or greater inhibition of tumor growth as compared with adoptive transfer of ex vivo retroviral-engineered T cells. Given that in vivo generation of CAR T cells resulted in transient CAR expression and circumvented the need for autologous T-cell isolation, viral vectors, and lymphodepletion, this platform represents a potentially safer, more accessible, and cost-effective method for targeting stromal cells to normalize the tumor microenvironment in desmoplastic tumors and has potential implications for tumor antigen–targeted CAR T cells.
- 2 April 2026
- Published by American Association for Cancer Research (AACR)
Open AccessData from Targeted Lipid Nanoparticle Delivery of FAP-CAR mRNA Enables Potent In Vivo T-cell Engineering against Pancreatic Tumors
Fibroblast activation protein (FAP), which is highly expressed on cancer-associated fibroblasts (CAF), is a promising therapeutic target to achieve normalization of the tumor microenvironment. We previously established an ex vivo retroviral-transduced FAP-specific chimeric antigen receptor (FAP-CAR) T-cell approach to deplete FAP+ CAFs that resulted in delayed tumor growth associated with disruption of desmoplastic matrix and enhanced immune cell infiltration and reversed immune exclusion and immunosuppression. In this study, we describe an in vivo strategy for generating FAP-CAR T cells using anti-CD5–conjugated targeted lipid nanoparticles (tLNP) encapsulating FAP-CAR mRNA and assessed the efficacy of this approach compared with adoptive transfer of retrovirus-transduced CAR T cells in a preclinical model of pancreatic ductal adenocarcinoma. With transient CAR expression in >45% of splenic, >69% of circulating, and >35% of tumor-infiltrating T cells, the abundance of peripheral and intratumoral FAP-CAR+ T cells detected following a single intravenous dose of FAP-CAR mRNA tLNPs was greater than that detected following administration of 1 × 107ex vivo retrovirally transduced FAP-CAR T cells. Furthermore, in vivo mRNA CAR T-cell engineering resulted in as good or greater inhibition of tumor growth as compared with adoptive transfer of ex vivo retroviral-engineered T cells. Given that in vivo generation of CAR T cells resulted in transient CAR expression and circumvented the need for autologous T-cell isolation, viral vectors, and lymphodepletion, this platform represents a potentially safer, more accessible, and cost-effective method for targeting stromal cells to normalize the tumor microenvironment in desmoplastic tumors and has potential implications for tumor antigen–targeted CAR T cells.
- Open Access
- 2 April 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 3 from Targeted Lipid Nanoparticle Delivery of FAP-CAR mRNA Enables Potent In Vivo T-cell Engineering against Pancreatic Tumors
Supplementary Figure 3. Kinetics of CD5-tLNO-FAP-CAR expression in primary murine T cells in vitro 24-, 48-, and 72-hour post incubation.
- 2 April 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 3 from Targeted Lipid Nanoparticle Delivery of FAP-CAR mRNA Enables Potent In Vivo T-cell Engineering against Pancreatic Tumors
Supplementary Figure 3. Kinetics of CD5-tLNO-FAP-CAR expression in primary murine T cells in vitro 24-, 48-, and 72-hour post incubation.
- Open Access
- 2 April 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 5 from Targeted Lipid Nanoparticle Delivery of FAP-CAR mRNA Enables Potent In Vivo T-cell Engineering against Pancreatic Tumors
Supplementary Figure 5. Characterization of FAP-CAR+ immune and stromal populations following in vivo T cell engineering.
- 2 April 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 5 from Targeted Lipid Nanoparticle Delivery of FAP-CAR mRNA Enables Potent In Vivo T-cell Engineering against Pancreatic Tumors
Supplementary Figure 5. Characterization of FAP-CAR+ immune and stromal populations following in vivo T cell engineering.
- Open Access
- 2 April 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 1 from Targeted Lipid Nanoparticle Delivery of FAP-CAR mRNA Enables Potent In Vivo T-cell Engineering against Pancreatic Tumors
Supplementary Figure 1. Flow cytometry gating strategy.
- 2 April 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 1 from Targeted Lipid Nanoparticle Delivery of FAP-CAR mRNA Enables Potent In Vivo T-cell Engineering against Pancreatic Tumors
Supplementary Figure 1. Flow cytometry gating strategy.
- Open Access
- 2 April 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 6 from Targeted Lipid Nanoparticle Delivery of FAP-CAR mRNA Enables Potent In Vivo T-cell Engineering against Pancreatic Tumors
Supplementary Figure 6. CAR Expression in Resting T Cells and in Tumors at 10 days Post-Treatment.
- 2 April 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 6 from Targeted Lipid Nanoparticle Delivery of FAP-CAR mRNA Enables Potent In Vivo T-cell Engineering against Pancreatic Tumors
Supplementary Figure 6. CAR Expression in Resting T Cells and in Tumors at 10 days Post-Treatment.
- Open Access
- 2 April 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 2 from Targeted Lipid Nanoparticle Delivery of FAP-CAR mRNA Enables Potent In Vivo T-cell Engineering against Pancreatic Tumors
Supplementary Figure 2. Flow cytometry gating strategy.
- 2 April 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 2 from Targeted Lipid Nanoparticle Delivery of FAP-CAR mRNA Enables Potent In Vivo T-cell Engineering against Pancreatic Tumors
Supplementary Figure 2. Flow cytometry gating strategy.
- Open Access
- 2 April 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 8 from Targeted Lipid Nanoparticle Delivery of FAP-CAR mRNA Enables Potent In Vivo T-cell Engineering against Pancreatic Tumors
Supplementary Figure 8. Comparative efficacy of in vivo and ex vivo CAR T cells.
- 2 April 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 8 from Targeted Lipid Nanoparticle Delivery of FAP-CAR mRNA Enables Potent In Vivo T-cell Engineering against Pancreatic Tumors
Supplementary Figure 8. Comparative efficacy of in vivo and ex vivo CAR T cells.
- Open Access
- 2 April 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 7 from Targeted Lipid Nanoparticle Delivery of FAP-CAR mRNA Enables Potent In Vivo T-cell Engineering against Pancreatic Tumors
Supplementary Figure 7. Robust and consistent anti-tumor activity of in vivo generated FAP-CAR T cells across multiple experiments.
- 2 April 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 7 from Targeted Lipid Nanoparticle Delivery of FAP-CAR mRNA Enables Potent In Vivo T-cell Engineering against Pancreatic Tumors
Supplementary Figure 7. Robust and consistent anti-tumor activity of in vivo generated FAP-CAR T cells across multiple experiments.